Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tel
Liquidia Corp (LQDA) shares fell 5.8% to $71.05, despite a 106% year-to-date increase, and are considered significantly undervalued according to GuruFocus's GF Value™ which estimates a fair value of $269.47. The company holds a GF Score™ of 70/100, driven by strong growth potential (10/10) and solid financial strength (7/10), but is tempered by a low profitability rank (4/10) and concerning insider selling totaling $237.9 million. Investors are advised to exercise caution due to a potential value trap and insider selling, despite the attractive valuation and growth prospects.
Liquidia Drops 5.9% Amid Sector-Wide Selling
Liquidia Corporation (LQDA) experienced a 5.9% drop on Thursday, closing at $70.91 per share, as specialty pharmaceutical stocks faced a broad selloff. The decline was accompanied by elevated trading volume, with 787,878 shares exchanged. This movement appears to be driven by broader sector dynamics rather than company-specific news, with several peers also recording significant losses.
Liquidia Corp (LQDA) CMO cashes in options, unloads 79K+ shares
Liquidia Corp's Chief Medical Officer, Rajeev Saggar, exercised non-qualified stock options for 50,000 shares at $3.73 per share. Concurrently, he sold 79,534 shares of common stock in two transactions: 29,534 shares at an average price of $76.84 and 50,000 shares at an average price of $74.06. Following these transactions, Saggar still holds 150,000 stock options, along with unvested RSUs and shares from an employee stock purchase plan.
Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock
Liquidia insider Rajeev Saggar sold 50,000 shares of the company's stock for $3.70 million, reducing his direct ownership by 26.01%. This follows two previous sales in August and July. Despite the insider selling, Liquidia's stock traded up 1.3%, and the company reported a significant year-over-year revenue increase, although it missed earnings expectations.
Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock
Liquidia (NASDAQ:LQDA) insider Rajeev Saggar sold 29,534 shares of the company's stock on August 17th for approximately $2.27 million, reducing his stake by 17.19%. This follows previous sales of 50,000 shares on August 19th and 9,926 shares on July 13th. The company recently reported strong revenue growth but slightly missed EPS estimates, and analysts currently hold a "Hold" consensus rating with an average price target of $98.08.
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia Corporation's lead drug, Yutrepia, has shown robust commercial performance since its launch, generating over $300 million in sales in the first half of 2026 and contributing to four consecutive profitable quarters for the company. Despite this strong growth and increasing physician adoption, Liquidia faces significant competition in the PAH market from established therapies like United Therapeutics' Tyvaso and Johnson & Johnson's various PAH drugs. Sustaining Yutrepia's momentum will depend on Liquidia's ability to execute effectively and differentiate its product in this competitive landscape.
Liquidia (NASDAQ: LQDA) director to sell shares after option exercises
Liquidia director Katherine T. Rielly-Gauvin plans to sell up to 55,182 shares of the company's common stock, valued at approximately $4.1 million. These shares will be acquired through the exercise of stock options and then sold via Morgan Stanley Smith Barney LLC. The transaction is detailed in a Form 144 SEC filing, indicating the shares will be received and sold over the next three months.
Renaissance Technologies LLC Sells 198,753 Shares of Liquidia Corporation $LQDA
Renaissance Technologies LLC has significantly reduced its stake in Liquidia Corporation (NASDAQ:LQDA) by selling 198,753 shares, retaining only 8,100 shares. Despite this, other institutional investors have increased their holdings. Liquidia's recent financial performance includes strong revenue growth but slightly missed EPS estimates, and analyst ratings are mixed with a "Hold" consensus.
Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA
Handelsbanken Fonder AB recently invested $1.99 million in Liquidia Corporation (LQDA) by acquiring 25,000 shares. Institutional investors now own 64.54% of the company, which reported strong revenue growth but missed EPS estimates. Analyst ratings are mixed, with a "Hold" consensus, while insiders have been selling shares.
Liquidia (NASDAQ: LQDA) affiliate plans new stock sale after $710K July trade
An affiliate of Liquidia Corporation (LQDA) plans to sell 29,534 shares of common stock, valued at approximately $2.27 million, through Morgan Stanley Smith Barney LLC around August 17, 2026. These shares are related to vested equity awards, including Performance Shares and Restricted Stock. This follows a previous sale by affiliate Rajeev Saggar of 9,926 common shares for $709,782.87 on July 13, 2026.
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia Corporation (LQDA) shares have fallen 15.4% following its Q2 earnings release, despite beating revenue and earnings estimates, due to the modest upside. The company's lead drug, Yutrepia, is driving significant revenue growth, but LQDA faces risks including overdependence on Yutrepia, a lean pipeline, ongoing patent litigation with United Therapeutics (UTHR), and competitive pressures from other PAH treatments, leading Zacks to issue a "Sell" rating.
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited
Greenhaven Road Capital reported an 11% net return in Q2 2026, indicating progress from the first quarter. The fund realized a short-term gain from Liquidia Corporation (NASDAQ:LQDA) after its shares appreciated more than 30% due to a successful drug launch despite an ongoing patent dispute. Greenhaven plans to revisit the investment in LQDA after the patent decision and will continue to focus on strong businesses and investments with near-term catalysts.
Liquidia (LQDA) Is Down 17.5% After Swinging To Q2 Profitability On Surging Revenue - Has The Bull Case Changed?
Liquidia (LQDA) swung to profitability in Q2 2026 with revenue of US$171.68 million, a significant increase from the previous year, and reported a net income of US$74.72 million. This rapid shift to profitability strengthens the near-term outlook for the company, largely driven by the success of YUTREPIA. However, investors still need to consider risks related to product concentration and potential impacts from ongoing patent disputes, despite the company's strong growth projections and recent inclusion in the S&P Composite 1500.
Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Zacks Research
Zacks Research has downgraded Liquidia (NASDAQ:LQDA) from a "strong-buy" to a "hold" rating. This follows various other analyst adjustments, resulting in an average "Hold" rating and a consensus price target of $98.08 for the stock. Despite a strong revenue beat driven by YUTREPIA sales, the company narrowly missed earnings estimates, leading to some negative sentiment and a lower Q3 2026 EPS forecast from HC Wainwright.
Liquidia Corp (LQDA) sees 6.5% stake reported by investor Paul B. Manning
Liquidia Corp investor Paul B. Manning and affiliated entities have reported an updated beneficial ownership of the company's common stock in Amendment No. 5 of their SEC filing. Manning now holds 6.5% of the common stock, with sole voting and dispositive power over 4,946,771 shares and shared power over 914,724 shares. The report details holdings by PD Joint Holdings, LLC, Series 2016-A and BKB Growth Investments, LLC, and clarifies the structure of Mr. Manning's beneficial ownership.
HC Wainwright Brokers Lower Earnings Estimates for Liquidia
HC Wainwright has lowered its Q3 2026 EPS estimate for Liquidia to $1.01 from $1.15, despite the company reporting explosive revenue growth of 1,842.1% year-over-year, driven by YUTREPIA sales. While Liquidia's EPS of $0.74 slightly missed consensus, analyst sentiment remains generally positive with a "Moderate Buy" rating and a $98.08 target price, though valuation concerns and increased R&D spending have introduced volatility. The article also details recent insider transactions and institutional holdings in Liquidia.
Why Liquidia Stock Was Diving This Week
Liquidia's stock fell 20% this week despite strong Q2 revenue of $171.7 million, largely due to successful sales of its pulmonary hypertension drug, Yutrepia. Although the company posted a net profit and slightly beat revenue estimates, it narrowly missed profit forecasts. The sell-off is primarily attributed to inflated investor expectations following a 155% year-to-date stock surge, suggesting that anything less than a "crushing, blowout quarter" would lead to a correction.
Liquidia Corp (LQDA) Shares Fall 8.5% -- What GF Score of 70 Tells Investors
Liquidia Corp (LQDA) shares fell 8.5% to $72.10, yet GuruFocus's GF Value™ suggests it is significantly undervalued by 72.7% with a GF Score™ of 70. Despite strong growth potential, the company faces mixed signals from insider activity, including substantial insider selling, and concerns about profitability and valuation. Investors are advised to consider these risks and monitor performance closely.
Liquidia (NASDAQ:LQDA) Trading Down 6.6% Following Weak Earnings
Liquidia (NASDAQ:LQDA) experienced a 6.6% stock drop after reporting weaker-than-expected quarterly earnings, with an EPS of $0.74 missing the $0.76 consensus estimate. Despite this, revenue exceeded expectations at $171.68 million, an 1842.1% increase year-over-year, driven by strong sales of its drug YUTREPIA. Concerns remain regarding the stock's high earnings multiple, insider selling, and anticipated higher research and development spending which could impact future margins.
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Liquidia Corporation (LQDA) reported strong second-quarter 2026 earnings, surpassing analyst estimates with EPS of 74 cents and total revenues of $171.7 million, primarily driven by robust sales of its lead drug, Yutrepia. Despite a 10% dip in shares post-announcement, the company's Yutrepia sales are accelerating, with over 5,000 patients started on therapy, and Liquidia expects to exceed $1 billion in net revenues by 2027 while continuing to grow profitability. The company is also advancing its pipeline with 10 clinical studies underway or planned for Yutrepia and L606, positioning it favorably against competitors like United Therapeutics.
Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat
Liquidia reported a strong second quarter, with total revenue of $171.7 million, exceeding Wall Street estimates, largely driven by sales of its inhaled lung disease drug, Yutrepia. Since its launch in June 2025, Yutrepia has received approximately 5,900 unique patient prescriptions and contributed significantly to the company's net product sales, which surged to $170.4 million. CEO Roger Jeffs noted the sustained adoption of Yutrepia, highlighting its increasing share in the growing inhaled prostacyclin market.
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia Corporation's Q2 2026 earnings call emphasized the growth of YUTREPIA, aiming for over $1 billion in net revenue by 2027 through commercial expansion and increased adoption. The company reported strong Q2 financial results, with EPS and revenues exceeding consensus estimates, and plans to increase R&D spending for its pipeline, including L606 and new YUTREPIA studies. Management also addressed ongoing patent litigation and patient adherence, expressing confidence in their legal arguments and YUTREPIA's tolerability.
Liquidia: YUTREPIA Reaches 5,000+ Patients As Inhaled Prostacyclin Market Expands Nearly 40%
Liquidia's YUTREPIA has reached over 5,000 patients and generated $170.4 million in Q2 net product sales, contributing to a nearly 40% expansion of the inhaled prostacyclin market since its launch. The company has seen four consecutive quarters of increasing profitability and is pursuing a broader strategy with its L606 extended-release formulation to expand its inhaled treprostinil franchise.
Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00
Bank of America has raised its price target for Liquidia (NASDAQ:LQDA) to $92.00 from $79.00, maintaining a "neutral" rating, indicating a potential 16.77% upside. This comes despite Liquidia's recent quarterly earnings showing revenue growth of 1,842.1% year-over-year to $171.68 million and net income of $74.7 million, though EPS slightly missed consensus estimates. The stock faces risks due to its high valuation with a P/E ratio over 560 and significant insider selling amounting to $124.4 million over the past 90 days.
Liquidia (LQDA) Turns Profitable In Q2, Is The Pullback A Valuation Opportunity?
Liquidia (LQDA) recently reported Q2 2026 results, shifting to profitability with increased revenue and positive net income, despite a recent share price pullback of over 10%. The company's stock has shown strong long-term performance, with a 212.66% return over the past year. Analysts see the company as undervalued, with a fair value of $130.00 against a recent close of $78.79, although its high P/S ratio of 27.2x raises concerns.
Needham & Company LLC Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price
Needham & Company LLC has raised its price target for Liquidia (NASDAQ:LQDA) to $110 from $70, maintaining a "buy" rating and implying a 39% upside. Despite strong Q2 2026 revenue of $171.7 million and net income of $74.7 million, the stock fell 10.2% after EPS of $0.74 narrowly missed estimates. Analysts generally have a "Moderate Buy" rating with an average target of $90, but insider selling and increased R&D spending are noted as potential concerns.
Earnings call transcript: Liquidia misses EPS in Q2 2026 as YUTREPIA sales surge
Liquidia Corporation reported a Q2 2026 earnings miss with EPS of $0.74 against an estimated $0.76, but surpassed revenue expectations with $171.6
Q2 2026 Liquidia Corp Earnings Call Transcript
Liquidia Corp (LQDA) reported strong Q2 2026 financial results with YUTREPIA net product sales of $170.4 million, a 31% quarter-over-quarter increase, and a net income of approximately $74.7 million. The company achieved four consecutive quarters of increasing profitability and ended the quarter with $284.2 million in cash. While facing legal uncertainties and rising R&D expenses, Liquidia projects over $1 billion in net revenue in 2027 driven by market expansion and increased share of the inhaled prostacyclin market.
Insight Wealth Strategies LLC Decreases Stock Position in Liquidia Corporation $LQDA
Insight Wealth Strategies LLC reduced its stake in Liquidia Corporation by 12.9% in the second quarter, selling 18,335 shares and retaining 124,067 shares worth approximately $9.84 million. While institutional investors like MPM Bioimpact and Bank of America increased their holdings, company insiders have been selling shares. Analysts maintain a "Moderate Buy" consensus with an average price target of $86.18, despite the company missing its recent quarterly earnings estimates.
Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary
Liquidia Corp reported strong financial results for the quarter ended 2026, with revenue reaching $171.68 million and diluted EPS of $0.74. This significant growth, representing an 1842.7% increase in revenue and 251% increase in diluted EPS year-over-year, was primarily driven by the successful commercial launch of YUTREPIA in June 2025. The company also highlighted continued promotion of Treprostinil Injection and increased R&D spending for new programs and additional YUTREPIA indications.
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Liquidia Corporation reported strong financial results for the second quarter of 2026, driven by significant sales of its YUTREPIA inhalation powder, which generated approximately $170.4 million. The company achieved its fourth consecutive quarter of increasing profitability with a net income of $74.7 million and an adjusted EBITDA of $96.3 million, alongside substantial growth in cash and cash equivalents. Liquidia also highlighted the continued adoption of YUTREPIA in the market and progress in 10 clinical studies for YUTREPIA and L606.
Liquidia earnings in focus as YUTREPIA launch faces patent test
Liquidia Technologies Inc. is reporting its second-quarter results with investors focusing on the commercial success of its new pulmonary hypertension drug, YUTREPIA, and the ongoing patent litigation. Analysts anticipate strong earnings and revenue growth, though the stock's recent surge reflects both high expectations and the critical importance of the legal outcome. The company's future hinges on YUTREPIA's sustained momentum, the resolution of its patent dispute, and its guidance for the latter half of 2026.
Sapient Capital LLC Has $1.83 Million Stake in Liquidia Corporation $LQDA
Sapient Capital LLC reduced its stake in Liquidia Corporation by 37.8% during the second quarter, now holding 23,000 shares valued at $1.83 million. Institutional investors collectively own 64.54% of Liquidia, while insiders sold approximately $125.8 million in stock, primarily due to tax obligations. Analysts maintain a "Moderate Buy" consensus with an average price target of $86.18, and Liquidia recently reported a significant 4,187.1% year-over-year revenue increase.
Farallon Capital Management Trims Liquidia Corp (LQDA) Stake -- Shares Trade 45% Below GF Value
Farallon Capital Management reduced its stake in Liquidia Corp (LQDA) by 3.36%, selling 291,000 shares at $79.73 each. Despite Liquidia's significant year-to-date gain of 189.9% and its stock trading 45% below its GF Value, GuruFocus labels it a "Possible Value Trap," advising caution due to high valuation metrics. The move by Farallon reflects a broader trend of profit-taking or risk management in the biopharmaceutical company.
Liquidia Corporation $LQDA Stock Holdings Lifted by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 63.3% in the first quarter, now holding 58,265 shares valued at $2.2 million. Institutional investors collectively own 64.54% of Liquidia. Analysts maintain a "Moderate Buy" rating with an average price target of $86.18, following strong quarterly revenue growth of 4,187.1% and earnings that beat expectations.
California State Teachers Retirement System Has $2.73 Million Stock Holdings in Liquidia Corporation $LQDA
The California State Teachers Retirement System increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 25% to 72,438 shares, now valued at approximately $2.73 million. Institutional investors collectively own 64.54% of the company, which has received a consensus "Moderate Buy" rating from analysts with an average price target of $86.18. Despite strong Q1 earnings exceeding estimates, company insiders have sold a significant amount of stock, totaling $125.8 million over the last 90 days.
Bank of America Corp DE Has $86.34 Million Stock Holdings in Liquidia Corporation $LQDA
Bank of America Corp DE increased its stake in Liquidia Corporation (LQDA) by 18.7% in the first quarter, holding over 2.2 million shares valued at approximately $86.3 million. Institutional investors and hedge funds collectively own 64.54% of LQDA. Liquidia reported strong quarterly earnings, beating analyst estimates with significant year-over-year revenue growth, yet insiders have recently sold a substantial number of shares.
Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of "Moderate Buy" from Brokerages
Liquidia Corporation (NASDAQ:LQDA) has received a "Moderate Buy" consensus rating from 11 brokerages, with an average 12-month price target of $86.18. The company recently surpassed quarterly earnings expectations, reporting $0.52 EPS against an anticipated $0.41, and revenue of $132.87 million, marking a significant year-over-year increase. Despite recent insider stock sales totaling $142.9 million, hedge funds and other institutions collectively own 64.54% of Liquidia’s stock.
Is Liquidia (LQDA) Overvalued After Its Third Straight Profitable Quarter?
Liquidia (LQDA) has achieved its third consecutive profitable quarter, driven by demand for its pulmonary hypertension therapy YUTREPIA and a significant financing agreement. Despite a recent surge in share price, leading to it trading above the average analyst price target, valuation models show conflicting results. While a narrative-driven fair value suggests the stock is overvalued at $72.38 compared to its current price of $90.22, a discounted cash flow (DCF) model estimates a much higher fair value of $360.34.
Liquidia Corporation (LQDA) Stock Forecasts
Liquidia Corp (LQDA) has received an Investment Rating of HOLD from Argus, with a target price raised to $93.00. The report details subratings for various financial aspects, categorizing the company's financial strength, growth, and value. Users can upgrade to premium services to access the full research report and additional insights.
FNY Investment Advisers LLC Acquires New Shares in Liquidia Corporation $LQDA
FNY Investment Advisers LLC has acquired 17,500 shares of Liquidia Corporation (NASDAQ:LQDA), valued at approximately $1.395 million, as Liquidia reported strong quarterly earnings with revenue up 4,187.1% year over year. Institutional investors collectively own 64.54% of the company, while insiders have recently sold a significant amount of shares. Analysts maintain a "Moderate Buy" rating with an average price target of $86.18, despite recent insider selling.
Zacks Investment Ideas feature highlights: Lenovo, Victoria's Secret and Liquidia
This article highlights three top-ranked stocks—Lenovo Group (LNVGY), Victoria's Secret (VSXY), and Liquidia Corp. (LQDA)—that are showing strong breakout potential due to positive earnings momentum and constructive price action. Each company benefits from a top Zacks Rank and is positioned for continued growth, with Lenovo expanding in AI, Victoria's Secret undergoing a successful brand turnaround, and Liquidia seeing explosive growth with its drug YUTREPIA. The analysis suggests these stocks offer compelling opportunities for momentum-oriented investors despite their distinct risks.
Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's Why
Liquidia (NASDAQ:LQDA) reached a new 52-week high of $91.36, closing up 1.6% at $90.87, driven by positive analyst sentiment and strong quarterly earnings, where revenue surged over 4,000%. Despite this, company insiders sold approximately 2.18 million shares worth $143.9 million in the last 90 days. The company's stock has a "Moderate Buy" consensus rating with an average price target of $86.18 from analysts.
Zacks Investment Ideas feature highlights: Lenovo, Victoria's Secret and Liquidia
Zacks Investment Ideas highlights three top-ranked stocks: Lenovo Group, Victoria's Secret, and Liquidia Corp., all showing strong earnings momentum and positive price action. Lenovo is transforming into an AI hardware provider with significant revenue growth, Victoria's Secret is undergoing a successful brand turnaround with improved financial results, and Liquidia Corp. is experiencing explosive commercial success with its YUTREPIA drug for cardiopulmonary diseases. All three companies are deemed compelling opportunities for momentum investors.
Farallon Group discloses 8.37M Liquidia (LQDA) shares, a 9.4% ownership stake
Farallon Capital Management, L.L.C. and related entities have disclosed an 8.37 million share beneficial ownership stake in Liquidia Corporation (LQDA), representing 9.4% of the company's outstanding common stock. This information was filed via an amended Schedule 13G/A, indicating shared voting and dispositive power over these shares. The investment is held by various Farallon investment partnerships, with Farallon Capital Management acting as the investment manager.
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
Liquidia Corporation (LQDA) is set to release its Q2 earnings on August 12, with strong sales and EPS estimates. The company has a positive earnings surprise history and its Yutrepia inhalation powder is a key growth driver, with impressive adoption rates. Despite competition, especially from United Therapeutics, Liquidia's strong commercial momentum and self-funded growth strategy make it a recommended investment.
Liquidia Corp (LQDA) Institutional Confidence
Liquidia Corp (LQDA) has an institutional shareholding score of 7.00, ranking 50 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 73.52%, showing a quarter-over-quarter increase of 0.02%. Farallon Capital Management, L.L.C. is a significant institutional shareholder, holding 8.66 million shares.
LQDA|Liquidia Corp|Price:86.870|Chg%:+0.050
This article provides a detailed financial overview of Liquidia Corp (LQDA), including its stock performance, key financial indicators like EPS, revenue, net profit, and gross margin across various quarters and fiscal years. It also presents the company's balance sheet and cash flow statement data, along with FAQs addressing specific financial metrics from its FY2025 earnings report. The information is designed to offer smart investors a comprehensive analysis of the company's financial health.
LQDA|Liquidia Corp|Price:85.495|Chg%:-1.325
This article provides a comprehensive stock analysis of Liquidia Corp (LQDA) from TradingKey, highlighting that its fundamentals are strong with high growth potential, and its valuation is considered fairly valued within the Pharmaceuticals industry. Despite strong fundamentals and stock performance, technical indicators show the stock trading sideways, suitable for range-bound swing trading. Analysts generally rate it as a "Buy" with a projected upward trend in the medium term.
Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares of Stock
Liquidia's Chief Accounting Officer, Dana Boyle, sold 1,600 shares of the company's stock for $140,048 on July 27th, 2026. This sale, executed under a Rule 10b5-1 plan, reduced her stake by 0.94% and was done to cover tax withholding obligations. The company's shares are trading near their 12-month high, following strong quarterly results that exceeded analyst expectations.
